Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia
Zuzana Walker 1 2 , Federica Gandolfo 3 , Stefania Orini 3 , Valentina Garibotto 4 , Federica Agosta 5 , Javier Arbizu 6 , Femke Bouwman 7 , Alexander Drzezga 8 , Peter Nestor 9 10 , Marina Boccardi 11 12 , Daniele Altomare 12 13 , Cristina Festari 12 13 , Flavio Nobili 14 , EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders
Purpose: There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of patients with idiopathic Parkinson's disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD from progressive supranuclear palsy, and (3) identifying the underlying neuropathology in corticobasal syndrome.
Methods: We therefore performed three literature searches and evaluated the selected studies for quality of design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were the sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiving operating characteristic curve, and positive/negative likelihood ratio of FDG PET in detecting the target condition. Using the Delphi method, a panel of seven experts voted for or against the use of FDG PET based on published evidence and expert opinion.
Results: Of 91 studies selected from the three literature searches, only four included an adequate quantitative assessment of the performance of FDG PET. The majority of studies lacked robust methodology due to lack of critical outcomes, inadequate gold standard and no head-to-head comparison with an appropriate reference standard. The panel recommended the use of FDG PET for all three clinical scenarios based on nonquantitative evidence of clinical utility.
Conclusion: Despite widespread use of FDG PET in clinical practice and extensive research, there is still very limited good quality evidence for the use of FDG PET. However, in the opinion of the majority of the panellists, FDG PET is a clinically useful imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia.
CITATION Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1534-1545. doi: 10.1007/s00259-018-4031-2. Epub 2018 May 19